SEC Form 4 · accession 0001209191-15-058891
Regulus Therapeutics Inc. · RGLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
ISIS PHARMACEUTICALS INC
10% Owner
Period of report
Jun 30, 2015
Accepted (ET)
Jul 2, 2015 · 4:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001505512
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 23, 2015 | G | 13,248 | $0.00 | A | 5,529,553 | D | |
| Common StockF2 | Jun 30, 2015 | S | 13,248 | $10.7948 | D | 5,516,305 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares were acquired pursuant to a transfer without consideration from Stanley Crooke, M.D., Ph.D., a former director of the Board of RGLS, immediately upon an exercise by Dr. Crooke of a stock option pursuant to which he acquired such shares.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.76 to $10.84 inclusive. The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.